Bloomberg
Votes & Verdicts
Votes and Verdicts is a series that examines the intersection of business, policy and law. It features conversations between Bloomberg Intelligence's team of litigation and policy analysts and thought leaders discussing legal and policy issues affecting markets and business decisions across many sectors.
Be sure to visit the podcast's website and support the creator: www.iheart.com
Where to listen?
Podcasts in the app Replaio Radio Coming soonPodcasts are coming to the app soon. Install now and be the first to see a whole new take on podcasts
Episodes
Net Neutrality Gets Another Day in Court 01.07.2024 9:46
Can the FCC regulate broadband service? Bloomberg Intelligence analyst Matt Schettenhelm joins colleague Jennifer Rie in this Votes and Verdicts brief to discuss the FCC’s latest advance of net-neutrality rules. They explore how the legal challenge to the agency’s rules is likely to play out. See omnystudio.com/listener for privacy information.
Calabria on Fannie, Freddie Conservatorships 10.06.2024 53:10
What’s the path and timeline for Fannie Mae and Freddie Mac to exit conservatorship? How should the Federal Housing Finance Agency’s independence be restored? Did the FHFA exceed its authority in implementing the Fannie-Freddie profit sweep? How should the Basel III Endgame proposal be improved? Do other regulators have problematic work environments like the FDIC? In this episode of the Votes and...
Catalysts for Apple, Alphabet, GSK, and Visa 05.06.2024 43:58
A Supreme Court ruling on First Amendment shields for Alphabet, Meta and other big-tech platforms, a liability verdict in the Justice Department’s antitrust case v. Google, and a hearing on a proposed $30 billion class settlement between Visa, Mastercard, credit card issuers and merchants are June catalysts to watch. In this litigation and policy outlook episode of Bloomberg Intelligence’s Votes a...
Todd Phillips on Basel III, Chevron, Crypto 31.05.2024 43:46
Biden-era rules are facing skeptical courts, creating a pivotal moment for US financial regulation impacting banks, asset managers and crypto platforms. Billions of dollars in relief could be heading to the industry if such rules are overturned. Bloomberg Intelligence analysts Nathan Dean and Elliott Stein host Todd Phillips, assistant professor of law, Robinson College of Business at Georgia Stat...
Durbin on Credit Cards, Airline Programs 23.05.2024 21:33
The Credit Card Competition Act, a bid to lower fees for retailers and consumers, could increase competitive pressures for Visa and Mastercard if enacted. The bill requires banks above $100 billion in assets to offer more than one credit-card network. Bloomberg Intelligence analysts Nathan Dean and Elliott Stein hosted US Senator Dick Durbin of Illinois to discuss the measure. They also examine wh...
Medicare’s Hospital-at-Home and Other Reforms 17.05.2024 36:41
Bloomberg Intelligence analyst Duane Wright discusses delivery-system reform and the hospital-at-home program with Mark Prather, on this episode of the Votes and Verdicts podcast. Mark is the co-founder and executive chairman of DispatchHealth, a leading in-home medical provider company. They discuss Mark’s background as a board-certified emergency medicine specialist, the spark that led him to fo...
Is TikTok on the Countdown to a Shutdown? 09.05.2024 37:34
ByteDance has signaled it won’t comply with a new US law requiring it to sell its TikTok video-sharing app, setting the stage for what likely will be a lengthy legal battle that could end up at the Supreme Court. TikTok faces rising pressure of a ban in the US if China-based ByteDance doesn’t divest the app. BI Analysts Matthew Schettenhelm, Tamlin Bason and Mandeep Singh analyze what’s at stake f...
Google, LiveNation, Uber and Other Catalysts 03.05.2024 36:59
Closing arguments in the Justice Department’s antitrust case v. Google, a possible DOJ antitrust lawsuit against LiveNation and a key hearing for Lyft and Uber in California’s Supreme Court are important May catalysts to watch. This Bloomberg Intelligence litigation and policy outlook episode, hosted by financials litigation analyst Elliott Stein, gathered the team to discuss these and other devel...
Kelleher on FinReg, ‘Kangaroo’ Courts 18.04.2024 46:46
The status of US financial regulation, including the SEC’s climate-change disclosure rule, the Basel III endgame, cryptocurrencies and potential proposals on executive compensation were topics of discussion as Bloomberg Intelligence analysts Elliott Stein and Nathan Dean hosted Better Markets CEO and Co-Founder Dennis Kelleher. They also discussed how US regulation is changing in light of new cour...
Pharma and Biotech Drug Pricing Policy Outlook 11.04.2024 1:04:57
Bloomberg Intelligence analysts Duane Wright and Aude Gerspacher look ahead in this edition of the Votes and Verdicts podcast and talk about key policy, regulatory and litigation issues to watch in the therapeutics sector. They discuss the implementation and legal hurdles for Inflation Reduction Act (IRA) drug pricing, the outlook for Medicare’s obesity drug coverage, the 340B drug-discount progra...
Antitrust Enforcers’ New Merger Guidelines 21.03.2024 28:15
Merger guidelines used by the Federal Trade Commission and Department of Justice to assess the antitrust impact of transactions were updated and revised in 4Q. In this episode of the Votes and Verdicts podcast, Edelman Smithfield Managing Director Ira Gorsky joins Bloomberg Intelligence analyst Jennifer Rie to discuss the implications of several of the changes. They focus on areas of the guideline...
Eugene Scalia on Beating Regulators in Court 12.03.2024 50:52
Bloomberg Intelligence analysts Elliott Stein and Nathan Dean hosted Eugene Scalia, former Secretary of Labor and current Administrative Law and Regulatory Practice Group co-chair at Gibson Dunn, to discuss lawsuits challenging government regulations. The conversation included a discussion of Chevron deference, the Basel III endgame, SEC and California climate disclosure laws and the SEC’s private...
Market and Reimbursement Outlook for Cell and Gene Therapies 07.03.2024 37:07
Cell and gene therapies are a scientific advancement that can treat previously uncurable diseases. Yet absent a national coverage and payment framework, they will remain out of reach for patients, according to Amanda Katchmar and Alan Cohen from Boston University. They join Bloomberg Intelligence analysts Duane Wright and Ann-Hunter Van Kirk on this episode of the Votes & Verdicts podcast to d...
3M, Synopsys, Capital One & Other Catalysts 01.03.2024 51:24
Regulatory and enforcement review of the Synopsys-Ansys and Capital One-Discover deals, finalized PFAS rules by the EPA, and the SEC’s climate disclosure rule are important March catalysts to watch. This Bloomberg Intelligence litigation and policy outlook episode, hosted by financials litigation analyst Elliott Stein, gathered the team to discuss these and other catalysts. In addition, Meta’s sui...
Can Legal State Pot Put US Law Up in Smoke? 27.02.2024 39:06
As federal action to reschedule, legalize or otherwise regulate the marijuana trade lingers, legitimate cannabis operations in states where pot is now legal continue to face significant barriers to programs and services, largely because the federal Controlled Substances Act still outlaws the drug. Among the many hurdles encountered by these businesses are a lack of access to federal tax credits an...
Biden’s Lab-Developed Test Proposal 20.02.2024 46:43
The Biden administration has proposed to extend medical-device oversight to laboratory developed tests. But doing so could increase compliance costs for test developers and reduce patient access to widely used tests, according to Susan Van Meter, President of the American Clinical Laboratory Association. She joins Bloomberg Intelligence analyst Duane Wright on this episode of the Votes & Verdi...
Biden’s Drug-Pricing Expansion Plan, Part 2 13.02.2024 57:03
The Biden administration’s proposal to expand the Bayh-Dole march-in framework to include price as a factor in determining that a drug isn’t accessible to the public could change collaboration agreements between universities and biotech companies. But the effort is inconsistent with the legislative intent of the framework, according to Joe Allen, executive director of the Bayh-Dole Coalition. He j...
Apple, Bayer, Moderna and Other Catalysts 02.02.2024 39:29
Apple’s choices to deal with an Apple-Watch import ban, a key hearing in Arbutus v. Moderna Covid-19 patent litigation, and more trials and a critical appeal in Bayer litigation over weed-killer Roundup are important February catalysts to watch. This Bloomberg Intelligence litigation and policy outlook episode, hosted by financials litigation analyst Elliott Stein, gathered the team to discuss the...
Apple’s Antitrust App-Store Battle With Epic 25.01.2024 58:04
The US Supreme Court this month refused to consider Apple’s appeal in an antitrust suit challenging its App Store. In this Votes & Verdicts episode, NYU Law Professor Harry First and Bloomberg Intelligence analysts Jennifer Rie, Anurag Rana and Tamlin Bason discuss the Epic Games v. Apple litigation and other antitrust risks Apple is facing in the US and the EU. They also look at Apple’s plans...
Washington’s Crowded Outlook for 2024 23.01.2024 46:58
Bloomberg Intelligence analysts Elliott Stein and Nathan Dean hosted Veda Partners Director of Economic Policy Research Henrietta Treyz and BTIG Director of Policy Research Isaac Boltansky to discuss their views on policies, impacts and outcomes in Washington over the coming year in this episode of the BI Votes and Verdicts podcast. Their conversation ranges from the anticipated rematch between Pr...
Biden’s Drug Pricing March-in Proposal 18.01.2024 45:38
The Biden administration proposes to expand the march-in framework to include price as a factor in determining that a drug isn’t accessible to the public. March-in rights allow the US government to license to another entity patents covering inventions developed with the help of taxpayer dollars and could apply to a handful of drugs. Dr. Aaron Kesselheim of the Harvard Medical School joins Bloomber...
Meta’s Biggest Legal, Regulatory Questions 18.12.2023 35:25
Meta faces litigation and policy risks across the EU and the US. In this episode of the Votes and Verdicts podcast, BI analysts from the tech and litigation & government teams — Jennifer Rie, Tamlin Bason and Matt Schettenhelm — give an overview of material legal issues for Meta investors to monitor. See omnystudio.com/listener for privacy information.
Antitrust Changes Could Hinder M&A 11.12.2023 53:51
Proposed changes at the US Federal Trade Commission and the Department of Justice to the rules and guidelines applicable to mergers and acquisitions may have a significant impact, making filing and completing M&A more difficult, burdensome and time-consuming. BI litigation analyst Jennifer Rie is joined by Morten Skroejer, senior director for technology competition policy at the Software &...
Apple, Disney, Novo Nordisk, Other Catalysts 01.12.2023 32:55
Apple facing an import ban on its watches, a key hearing in Disney v. Florida and a Novo Nordisk claim construction hearing in a $98 billion patent suit to block Mylan’s copy of weight-loss drug Wegovy are key December catalysts to watch. This Bloomberg Intelligence litigation and policy outlook episode, hosted by financials litigation analyst Elliott Stein, gathered the team to discuss these and...
J&J, 3M's Chap 11 Play in Talc, Earplug Mass Torts 14.11.2023 31:56
Johnson & Johnson, facing tens of thousands of lawsuits over allegations its talcum powder causes cancer, has twice attempted to use bankruptcy proceedings to reach global resolution of cases, and twice has failed. Will a potential third bankruptcy attempt by its unit bear different results? 3M, which faced hundreds of thousands of lawsuits over allegedly defective earplugs, attempted and fail...
Similar podcasts
Replaio is not a podcast publisher; show names, artwork and audio belong to their authors and are distributed through public RSS feeds.